1. European Commission (2005) Commission directive 2005/28/EC. Off J Eur Union L91:13–19
2. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (1996) Guidelines for good clinical practices E6(R1). http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf . Accessed 27 March 2015
3. U.S. Department of Health and Human Services, Food and Drug Administration (2013) Guidance for industry: oversight of clinical investigations—a risk-based approach to monitoring. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM269919.pdf . Accessed 20 February 2015
4. Duley L, Antman K, Arena J et al (2008) Specific barriers to the conduct of randomized trials. Clin Trials 5:40–48
5. De S (2011) Hybrid approaches to clinical trial monitoring: practical alternatives to 100% source data verification. Perspect Clin Res 2:100–104